Payment overview · 2025
General Payments
$892.01
67 reported records · 15 companies
Healthcare provider profile · identity verified
Jesse E Morriss, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DOTHAN, AL · NPI 1063481273
Verified facts
What the public records show
CMS Open Payments records show Jesse E Morriss, MD received $892.01 in general payments during 2025 across 67 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Airsupra, Eliquis, Farxiga, Jardiance, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1292 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $159.26 | 17.9% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $150.43 | 16.9% | 18 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $149.53 | 16.8% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $142.04 | 15.9% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $58.40 | 6.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.11 | 4.4% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $33.94 | 3.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.55 | 3.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.34 | 3.4% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.71 | 2.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.23 | 2.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.35 | 1.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.38 | 1.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.93 | 1.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.81 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $892.01 | 67 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $149.53 | 13 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $126.23 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $101.37 | 11 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $73.51 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $72.15 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $62.60 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $58.40 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $55.52 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $53.83 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $39.11 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $39.11 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $33.94 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $30.34 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $5.93 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $0.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1292 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 116 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 68 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 130 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
174 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
82 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
98 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
116 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
82 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
130 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
162 | 23 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1292 | 105 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
127 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 2702 | 346 |
| Amlodipine Besylate | Amlodipine Besylate | 2389 | 338 |
| Atorvastatin Calcium | Atorvastatin Calcium | 2141 | 310 |
| Potassium Chloride | Potassium Chloride | 2008 | 250 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1765 | 266 |
| Omeprazole | Omeprazole | 1417 | 181 |
| Gabapentin | Gabapentin | 1363 | 237 |
| Eliquis | Apixaban | 1292 | 105 |
| Sertraline Hcl | Sertraline Hcl | 1191 | 171 |
| Losartan Potassium | Losartan Potassium | 1183 | 192 |
| Furosemide | Furosemide | 1040 | 141 |
| Lisinopril | Lisinopril | 986 | 147 |
| Bumetanide | Bumetanide | 977 | 119 |
| Metoprolol Tartrate | Metoprolol Tartrate | 916 | 123 |
| Mirtazapine | Mirtazapine | 913 | 104 |
| Tamsulosin Hcl | Tamsulosin Hcl | 889 | 140 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 828 | 168 |
| Donepezil Hcl | Donepezil Hcl | 803 | 97 |
| Memantine Hcl | Memantine Hcl | 783 | 90 |
| Alprazolam | Alprazolam | 724 | 123 |
| Clopidogrel | Clopidogrel Bisulfate | 722 | 103 |
| Tramadol Hcl | Tramadol Hcl | 715 | 182 |
| Duloxetine Hcl | Duloxetine Hcl | 688 | 90 |
| Metformin Hcl | Metformin Hcl | 664 | 113 |
| Metoprolol Succinate | Metoprolol Succinate | 660 | 93 |
| Carvedilol | Carvedilol | 589 | 73 |
| Trazodone Hcl | Trazodone Hcl | 586 | 105 |
| Montelukast Sodium | Montelukast Sodium | 584 | 83 |
| Escitalopram Oxalate | Escitalopram Oxalate | 562 | 65 |
| Xarelto | Rivaroxaban | 534 | 50 |
| Simvastatin | Simvastatin | 527 | 85 |
| Hydralazine Hcl | Hydralazine Hcl | 520 | 57 |
| Levetiracetam | Levetiracetam | 501 | 50 |
| Januvia | Sitagliptin Phosphate | 496 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 485 | 62 |
| Quetiapine Fumarate | Quetiapine Fumarate | 476 | 63 |
| Pravastatin Sodium | Pravastatin Sodium | 465 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 456 | 90 |
| Buspirone Hcl | Buspirone Hcl | 446 | 74 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 440 | 38 |
| Meloxicam | Meloxicam | 435 | 140 |
| Citalopram Hbr | Citalopram Hydrobromide | 388 | 56 |
| Sucralfate | Sucralfate | 388 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 383 | 55 |
| Myrbetriq | Mirabegron | 364 | 38 |
| Ropinirole Hcl | Ropinirole Hcl | 347 | 45 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 327 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 316 | 42 |
| Paroxetine Hcl | Paroxetine Hcl | 314 | 35 |
| Allopurinol | Allopurinol | 306 | 60 |
| Fluoxetine Hcl | Fluoxetine Hcl | 300 | 36 |
| Bupropion Xl | Bupropion Hcl | 292 | 76 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 283 | 58 |
| Divalproex Sodium | Divalproex Sodium | 273 | 29 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 273 | 164 |
| Clonidine Hcl | Clonidine Hcl | 265 | 59 |
| Clonazepam | Clonazepam | 263 | 45 |
| Entresto | Sacubitril/Valsartan | 252 | 18 |
| Midodrine Hcl | Midodrine Hcl | 252 | 38 |
| Famotidine | Famotidine | 249 | 38 |
| Methocarbamol | Methocarbamol | 243 | 88 |
| Spironolactone | Spironolactone | 237 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 229 | 33 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 228 | 32 |
| Prednisone | Prednisone | 225 | 57 |
| Pregabalin | Pregabalin | 218 | 37 |
| Atenolol | Atenolol | 217 | 30 |
| Metolazone | Metolazone | 212 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 205 | 80 |
| Azithromycin | Azithromycin | 200 | 155 |
| Finasteride | Finasteride | 194 | 38 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 192 | 35 |
| Diltiazem Hcl | Diltiazem Hcl | 189 | 15 |
| Digoxin | Digoxin | 187 | 15 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 182 | 34 |
| Mirabegron Er | Mirabegron | 180 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 178 | 49 |
| Linzess | Linaclotide | 174 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 174 | 35 |
| Baclofen | Baclofen | 171 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 170 | 131 |
| Ranolazine Er | Ranolazine | 169 | 17 |
| Temazepam | Temazepam | 165 | 29 |
| Meclizine Hcl | Meclizine Hcl | 163 | 42 |
| Trulicity | Dulaglutide | 162 | 23 |
| Ozempic | Semaglutide | 161 | 33 |
| Tizanidine Hcl | Tizanidine Hcl | 158 | 29 |
| Nifedipine Er | Nifedipine | 157 | 32 |
| Risperidone | Risperidone | 156 | 14 |
| Glimepiride | Glimepiride | 155 | 31 |
| Lorazepam | Lorazepam | 155 | 27 |
| Topiramate | Topiramate | 149 | 19 |
| Nebivolol Hcl | Nebivolol Hcl | 139 | 27 |
| Olanzapine | Olanzapine | 136 | 13 |
| Methenamine Hippurate | Methenamine Hippurate | 134 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 133 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 133 | 52 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 133 | 104 |
| Fenofibrate | Fenofibrate | 132 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 132 | 44 |
| Mounjaro | Tirzepatide | 130 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 129 | 26 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 127 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 125 | 36 |
| Cephalexin | Cephalexin | 124 | 73 |
| Ceftriaxone | Ceftriaxone Sodium | 123 | 70 |
| Celecoxib | Celecoxib | 122 | 32 |
| Farxiga | Dapagliflozin Propanediol | 116 | 28 |
| Ezetimibe | Ezetimibe | 115 | 29 |
| Lamotrigine | Lamotrigine | 115 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 112 | 94 |
| Diazepam | Diazepam | 110 | 25 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 109 | 30 |
| Amiodarone Hcl | Amiodarone Hcl | 105 | 22 |
| Lidocaine Hcl | Lidocaine Hcl | 105 | 64 |
| Nystatin | Nystatin | 104 | 49 |
| Ondansetron Odt | Ondansetron | 104 | 41 |
| Testosterone Cypionate | Testosterone Cypionate | 104 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 103 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 46 |
| Estradiol | Estradiol | 101 | 29 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 101 | 23 |
| Colesevelam Hcl | Colesevelam Hcl | 100 | 22 |
| Benazepril Hcl | Benazepril Hcl | 99 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 99 | 36 |
| Brilinta | Ticagrelor | 98 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 98 | 13 |
| Venlafaxine Hcl | Venlafaxine Hcl | 98 | suppressed |
| Levemir | Insulin Detemir | 97 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 94 | 18 |
| Levofloxacin | Levofloxacin | 94 | 68 |
| Primidone | Primidone | 93 | 20 |
| Rivastigmine | Rivastigmine Tartrate | 93 | suppressed |
| Lactulose | Lactulose | 92 | 29 |
| Latanoprost | Latanoprost | 90 | 19 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 90 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 89 | 16 |
| Dexlansoprazole Dr | Dexlansoprazole | 87 | suppressed |
| Fluconazole | Fluconazole | 87 | 68 |
| Rivastigmine | Rivastigmine | 86 | 14 |
| Aripiprazole | Aripiprazole | 85 | 13 |
| Diltiazem 24hr Er | Diltiazem Hcl | 83 | suppressed |
| Novolog | Insulin Aspart | 82 | 27 |
| Synthroid | Levothyroxine Sodium | 82 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 16 |
| Alendronate Sodium | Alendronate Sodium | 79 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 79 | 21 |
| Warfarin Sodium | Warfarin Sodium | 79 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 78 | 26 |
| Fentanyl | Fentanyl | 77 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 77 | 12 |
| Albuterol Sulfate | Albuterol Sulfate | 75 | 43 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 73 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 72 | 45 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 21 |
| Sotalol | Sotalol Hcl | 71 | suppressed |
| Glipizide | Glipizide | 70 | 16 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 69 | suppressed |
| Jardiance | Empagliflozin | 68 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 68 | 11 |
| Lidocaine | Lidocaine | 67 | 15 |
| Humalog | Insulin Lispro | 66 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 66 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 65 | 18 |
| Cefdinir | Cefdinir | 65 | 58 |
| Clonidine | Clonidine | 65 | suppressed |
| Ertapenem | Ertapenem Sodium | 64 | 33 |
| Valacyclovir | Valacyclovir Hcl | 64 | 29 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 63 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 62 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 61 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 57 | suppressed |
| Novolin R | Insulin Regular, Human | 56 | 14 |
| Eszopiclone | Eszopiclone | 55 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 52 | 28 |
| Humalog Kwikpen U-100 | Insulin Lispro | 52 | 15 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 52 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 51 | suppressed |
| Ketoconazole | Ketoconazole | 50 | 17 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 49 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 49 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 48 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 47 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | 11 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 46 | suppressed |
| Multaq | Dronedarone Hcl | 46 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 46 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 45 | 13 |
| Megestrol Acetate | Megestrol Acetate | 45 | 15 |
| Doxepin Hcl | Doxepin Hcl | 43 | suppressed |
| Lansoprazole | Lansoprazole | 43 | 11 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 42 | suppressed |
| Indapamide | Indapamide | 42 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 22 |
| Colchicine | Colchicine | 41 | 17 |
| Metformin Hcl Er | Metformin Hcl | 41 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 40 | suppressed |
| Constulose | Lactulose | 40 | 13 |
| Lubiprostone | Lubiprostone | 40 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 40 | suppressed |
| Metronidazole | Metronidazole | 40 | 24 |
| Nystop | Nystatin | 40 | 27 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 40 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 39 | suppressed |
| Mupirocin | Mupirocin | 39 | 25 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | suppressed |
| Verapamil Er | Verapamil Hcl | 38 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 37 | 30 |
| Propranolol Hcl Er | Propranolol Hcl | 36 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 36 | suppressed |
| Tradjenta | Linagliptin | 36 | suppressed |
| Dexamethasone | Dexamethasone | 35 | 13 |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 35 | 29 |
| Ibandronate Sodium | Ibandronate Sodium | 35 | suppressed |
| Methimazole | Methimazole | 35 | suppressed |
| Minoxidil | Minoxidil | 35 | suppressed |
| Zonisamide | Zonisamide | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 29 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 34 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 34 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 34 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 34 | suppressed |
| Methotrexate | Methotrexate Sodium | 34 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 34 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 34 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 34 | suppressed |
| Carbamazepine Er | Carbamazepine | 33 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 33 | 23 |
| Valsartan | Valsartan | 33 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 31 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 30 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 30 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 30 | 17 |
| Thioridazine Hcl | Thioridazine Hcl | 30 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 28 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 28 | suppressed |
| Phenytoin | Phenytoin | 28 | suppressed |
| Valproic Acid | Valproic Acid | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 22 |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Phenobarbital | Phenobarbital | 26 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 26 | suppressed |
| Sulfasalazine | Sulfasalazine | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Invokana | Canagliflozin | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Trimethoprim | Trimethoprim | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Humulin R | Insulin Regular, Human | 24 | suppressed |
| Lumigan | Bimatoprost | 24 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Prednisolone Acetate | Prednisolone Acetate | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 23 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 23 | suppressed |
| Loperamide | Loperamide Hcl | 23 | 11 |
| Nuplazid | Pimavanserin Tartrate | 23 | suppressed |
| Creon | Lipase/Protease/Amylase | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 22 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 22 | 14 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 21 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 20 | 11 |
| Lithium Carbonate | Lithium Carbonate | 20 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 19 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 19 | suppressed |
| Hydroxyurea | Hydroxyurea | 19 | suppressed |
| Jantoven | Warfarin Sodium | 19 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Leflunomide | Leflunomide | 18 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Cilostazol | Cilostazol | 17 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 17 | 17 |
| Matzim La | Diltiazem Hcl | 17 | suppressed |
| Methadone Hcl | Methadone Hcl | 17 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 16 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 12 |
| Glipizide Er | Glipizide | 15 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 15 | 15 |
| Tresiba | Insulin Degludec | 15 | suppressed |
| Calcium Acetate | Calcium Acetate | 14 | suppressed |
| Glucagon Emergency Kit | Glucagon | 14 | suppressed |
| Insulin Aspart | Insulin Aspart | 14 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 14 | suppressed |
| Niacin Er | Niacin | 14 | suppressed |
| Restasis | Cyclosporine | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Chlordiazepoxide-Clidinium | Chlordiazepoxide/Clidinium Br | 13 | suppressed |
| Daptomycin | Daptomycin | 13 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 13 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Xcopri | Cenobamate | 13 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Captopril | Captopril | 12 | suppressed |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Ofloxacin | Ofloxacin | 12 | suppressed |
| Solu-Medrol | Methylprednisolone Sod Succ/Pf | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Cartia Xt | Diltiazem Hcl | 11 | suppressed |
| Felodipine Er | Felodipine | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Linezolid | Linezolid | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
| Topamax | Topiramate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $892.01 · 67 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, INSPIRE, JARDIANCE, Kerendia, Korlym, MOUNJARO, NEXLETOL, NURTEC ODT, OFEV, OTEZLA, PROLIA, REPATHA, REXULTI, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, ZEPBOUND | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Airsupra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error